AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
MapLight Therapeutics, Inc.
Video analysis: MPLT
All videosNo video analysis for this stock yet. Request one from our team.
News: MPLT
MapLight Therapeutics to Participate in Upcoming Investor Conference
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT
BlackRock Inc. acquired a new position in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,025,134 shares of the company's stock, valued at approximately $36,741,000. BlackRock Inc. owned 2.41% of Maplight Therapeutics at
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027 Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup Primarily focusing resources on the advancement of ML-007C-MA Ended the quarter with $351.3 million in cash, cash equivalents and investments, which, together with the Company's recent $150 million private placement, is expected to extend cash runway through 2028, including through the projected readouts for both VISTA and ZEPHYR-2 SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing ML-007C-MA in both schizophrenia and ADP,” said Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight.
MapLight Therapeutics Announces $150 Million Private Placement Financing
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $150 million, before deducting placement agent fees and estimated offering expenses. The financing is being led by new and existing institutional investors.
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMapLight Therapeutics, Inc. ("MapLight" or "the Company") (NASDAQ: MPLT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Maplight Therapeutics (NASDAQ:MPLT) Trading 18.2% Higher on Insider Buying Activity
Shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) rose 18.2% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $14.49 and last traded at $14.5480. Approximately 378,003 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 402,503 shares.
ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT
ADAR1 Capital Management LLC acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 374,909 shares of the company's stock, valued at approximately $7,622,000. ADAR1 Capital Management LLC owned
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
